Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
EP. 1: Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer
April 26th 2016
EP. 2: Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer
April 26th 2016
EP. 3: Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations
April 26th 2016
EP. 4: Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies
April 26th 2016
EP. 5: Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC
April 26th 2016
EP. 6: Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing
April 26th 2016
EP. 7: Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing
April 26th 2016
EP. 8: Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab
April 26th 2016
EP. 9: Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer
April 26th 2016
EP. 10: Charles Fuchs, MD: Clinical Importance of RAS Mutations
April 26th 2016
EP. 11: Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
April 26th 2016
EP. 12: Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC
April 26th 2016
EP. 13: Charles Fuchs, MD: Impeding RAS Mutation Testing
April 26th 2016
EP. 14: Charles Fuchs, MD: Strategies to Increase RAS Testing
April 26th 2016
EP. 15: Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab
April 26th 2016
